Inovio says no-go on phase 3 cervical lesion program after clinical setback, lays off 30% of staff

Inovio is making its third round of layoffs in 13 months. Facing a long path to approval, the biotech has stopped its cervical lesion program to focus on its most promising, closest-to-market options, putting 58 people out of work in the process.